Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050604 | 0.79 | BAZ2B (0.47) | TSHRHSD17B10POLBALDH1A1KDM4E | |
| SCHEMBL4069458 | 0.73 | SMN1; SMN2 (0.56) | TSHRPOLBALDH1A1KDM4EHPGD | |
| SCHEMBL1988689 | 0.68 | L3MBTL1 (0.46) | TSHRHSD17B10POLBALDH1A1KDM4E | |
| SCHEMBL1992228 | 0.67 | POLB (0.39) | TSHRHSD17B10POLBALDH1A1KDM4E | |
| SCHEMBL7111537 | 0.64 | BAZ2B (0.47) | TSHRHSD17B10ALDH1A1KDM4EHPGD | |
| SCHEMBL7485486 | 0.64 | ALDH1A1 (0.57) | TSHRHSD17B10POLBALDH1A1KDM4E | |
| SCHEMBL2457012 | 0.63 | KMT2A (0.64) | TSHRPOLBALDH1A1KDM4EMEN1 | |
| SCHEMBL8021031 | 0.63 | L3MBTL1 (0.63) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9494419 | 0.63 | TSHR (0.75) | TSHRHSD17B10ALDH1A1KDM4EHPGD | |
| SCHEMBL1844052 | 0.62 | TSHR (0.57) | TSHRHSD17B10POLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735320-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1735320-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7470705-B2 | e.g. Cis-4-[acety1-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H- [1,5]naphthyridine-1-carboxylic acid isopropyl ester; cholesterol ester transfer protein (CETP) inhibitors; increasing plasma HDL- cholesterol, decreasing plasma LDL- cholesterol; atherosclerosis | ELI LILLY AND COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470705-B2 | e.g. Cis-4-[acety1-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H- [1,5]naphthyridine-1-carboxylic acid isopropyl ester; cholesterol ester transfer protein (CETP) inhibitors; increasing plasma HDL- cholesterol, decreasing plasma LDL- cholesterol; atherosclerosis | ELI LILLY AND COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470705-B2 | e.g. Cis-4-[acety1-(3,5-bis-trifluoromethyl-benzyl)-amino]-2-ethyl-6-methoxy-3,4-dihydro-2H- [1,5]naphthyridine-1-carboxylic acid isopropyl ester; cholesterol ester transfer protein (CETP) inhibitors; increasing plasma HDL- cholesterol, decreasing plasma LDL- cholesterol; atherosclerosis | ELI LILLY AND COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1735320-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097806-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173526-A1 | Compounds and methods for treating dyslipidemia | PCSK9, APOB, LIPC | TSHR 1092/4885HSD17B10 150/4885POLB 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.